CSL Limited
CSLLY
Updated: 24/09/2026, 17:58:27
CSL Limited is a global biopharmaceutical enterprise dedicated to the research, development, production, marketing, and distribution of a wide array of biopharmaceutical and related healthcare products. The company boasts a significant international presence, with operations spanning major markets such as Australia, the United States, Germany, the United Kingdom, Switzerland, and China, alongside other territories worldwide. Its business is primarily structured around two key divisions: CSL Behring and Seqirus. The CSL Behring segment specializes in plasma-derived and recombinant therapies, which are crucial for treating serious medical conditions including immunodeficiency, various bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and certain neurological ailments. This division also conducts extensive research into both plasma and non-plasma-based treatments and generates income through licensing agreements and royalties from its proprietary innovations. In contrast, the Seqirus segment is focused on manufacturing and supplying biotherapeutic products that are not derived from plasma, with a particular emphasis on the development of solutions related to influenza. CSL Limited, originally founded in 1916, has its corporate headquarters situated in Parkville, Australia.
No summaries found.
- Share price
- $31.35
- Market cap
- $121.39B
- Exchange
- OTC
- Currency
- USD
- CEO
- Gordon Naylor DipCompSc
- Employees
- 29,000
- IPO date
- 29/12/2009
- Beta
- 0.08400000000000001
- Last dividend
- $0.00
- Day range
- $31.32 – $31.48
- 52-week range
- $16.01 – $36.29
- 1-day performance
- 0.15%
- 1-year performance
- 95.80%
- Current drawdown (1Y)
- -13.61%
- CIK
- 0001274152
- CUSIP
- 12637N204
- ISIN
- US12637N2045
- Created
- 07/12/2025, 03:28:29
- Last update
- 24/09/2026, 17:58:27
Track CSL Limited with an AI analyst
See which prediction-market events move CSLLY, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Australia says CSL unit Seqirus to discontinue Benpen injections from November
Reuters • STOCK • 27/05/2026, 05:20:38
CSL Limited (CSLLY) Shareholder/Analyst Call Transcript
Seeking Alpha • STOCK • 14/05/2026, 17:30:47
CSL: The Plasma Moat Is Being Rebuilt While The Market Prices The Noise
Seeking Alpha • STOCK • 05/05/2026, 05:44:37
Should Value Investors Buy CSL Limited (CSLLY) Stock?
Zacks Investment Research • STOCK • 04/05/2026, 12:40:37
CSLLY vs. ACAD: Which Stock Is the Better Value Option?
Zacks Investment Research • STOCK • 30/04/2026, 14:40:27
CSLLY vs. ACAD: Which Stock Should Value Investors Buy Now?
Zacks Investment Research • STOCK • 14/04/2026, 14:40:29
CSLLY or ARGX: Which Is the Better Value Stock Right Now?
Zacks Investment Research • STOCK • 24/03/2026, 13:41:06
CSLLY vs. ARGX: Which Stock Is the Better Value Option?
Zacks Investment Research • STOCK • 23/03/2026, 13:40:38
CSL announces expansion of Illinois plasma therapy manufacturing facility
PRNewsWire • STOCK • 09/03/2026, 12:01:00
CSLLY or EXAS: Which Is the Better Value Stock Right Now?
Zacks Investment Research • STOCK • 04/03/2026, 13:41:19
CSL signs licensing deal with Eli Lilly for clazakizumab to treat kidney disease
Reuters • STOCK • 17/02/2026, 17:26:38
CSLLY vs. EXAS: Which Stock Is the Better Value Option?
Zacks Investment Research • STOCK • 16/02/2026, 13:40:30